Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists - Summary - MDSpire
Advertisement
Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists
To investigate the association between GLP1a use and specific cardiovascular events and mortality in multiple myeloma patients with Type 2 diabetes receiving proteasome inhibitors.
Key Findings:
Patients on GLP1a had a statistically significant 33% lower risk of MACE compared to non-GLP1a patients (HR 0.67).
Patients on GLP1a had a statistically significant 43% lower risk of heart failure (HR 0.57).
Patients on GLP1a had a statistically significant 44% lower risk of all-cause mortality (HR 0.56).
No significant differences in rates of myocardial infarction, atrial fibrillation, and ischaemic stroke between cohorts.
Interpretation:
GLP1a use is associated with a significant reduction in cardiovascular events and mortality in diabetic patients with multiple myeloma treated with proteasome inhibitors, suggesting a potential protective role.
Limitations:
Retrospective design may introduce bias, potentially affecting the reliability of the findings.
Exclusion of patients with prior cardiovascular events limits generalizability to the broader population.
Conclusion:
GLP1a may provide cardiovascular and mortality benefits for multiple myeloma patients with Type 2 diabetes undergoing proteasome inhibitor treatment.
